Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Velcade bortezomib: Phase III data

In the international Phase III VISTA trial in 682 previously untreated MM patients ineligible for stem cell transplantation, Velcade plus melphalan and prednisone

Read the full 238 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE